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Summary The concentration of magnesium in serum has been shown to fall to potentially dangerously low
levels after several courses of treatment with cis-diamminedichloroplatinum II (cis-platin). The aims of this
study were to examine the effects of magnesium supplementation on predicted outcome of treatment, rate of
response to treatment and toxicity of treatment. Sixteen patients with testicular cancer were studied in detail
over a 14 month period. One patient with an ovarian dysgerminoma was also included in the study. Eight
patients were randomised to receive magnesium supplements both intravenous and oral; nine did not.
The non-supplemented group showed significantly greater renal tubular damage as assessed by urine N-
acetyl-B-D-glucosaminidase (NAG). There was a trend towards a reduction in treatment delays due to
neutropenic episodes in the supplemented group, and serum magnesium concentrations remained significantly
higher. Neither group showed differences in tumour growth rates or outcome. These results show that
magnesium supplements are of considerable benefit and show no harmful effects in patients receiving cis-
platin treatment. It is is suggested that magnesium supplements should be a routine part of the treatment
regime, and that these should comprise both i.v. supplements during treatment and oral supplements between
courses.
The concentration of magnesium in serum may fall
to potentially dangerous levels after several courses
of treatment with cis-diamminedichloroplatinum
(II) (cis-platin) which is used as part of a
combination chemotherapeutic regime for teratoma
and other tumours (Schilsky & Anderson, 1979;
Willox et al., 1981). There are problems in
recognising the clinical symptoms of
hypomagnesaemia such as tingling, weakness,
lethargy, depression and ataxia since these are not
uncommon side-effects of chemotherapy. Suggested
causes of the hypomagnesaemia due to cis-platin
are the nephrotoxicity of the drug resulting in a
specific magnesium-losing renal tubular defect
(Schilsky et al., 1982) and the anorexia, nausea, and
vomiting produced by cis-platin with consequent
reduced intake and loss in vomitus (Ohnuma &
Holland, 1977). In addition to hypomagnesaemia,
there may be accompanying hypokalaemia and
hypocalcaemia (Stuart-Harris et al., 1980) and this
has been seen in a number of our patients.
Parsons et al. (1974) have suggested that
magnesium depletion decreases tumour growth and
may therefore be beneficial to the host; however
our experience, during treatment of patients who
have teratoma or ovarian carcinoma with cis-platin,
suggests that the low magnesium levels produce
potentially serious additional problems. It has been
suggested that routine magnesium supplementation
become part of cis-platin-containing regimes
(Macaulay et al., 1982), although the value of this
approach has not previously been assessed in a
randomised fashion.
The aims of this study were therefore to analyse
the effects of magnesium supplementation on
predicted outcome of treatment, response to
treatment as assessed by rate of fall of tumour
markers, and toxicity of treatment as determined by
neutropenic episodes, septicaemia, anaemia and
blood transfusions, treatment delays, anorexia,
weight loss and renal damage in patients receiving
cis-platin for teratoma.
Methods
Over a 14 month period, every patient attending
the Department of Clinical Oncology, Gartnavel
General Hospital, Glasgow, for treatment of
teratoma with cis-platin was randomised to receive
magnesium supplements or not. One female patient
with dysgerminoma (ovary) was also included in
the study. Patients received a modified Einhorn
regime of treatment (Einhorn & Donohue, 1977)
comprising cis-platin 20mgm-2 i.v. for 5 days,
vinblastine 0.15mgkg-1 i.v. days 1 and 2, and
bleomycin 30mg i.m. on day 2, 9, 16, the whole
cycle being repeated every three weeks. Four litres
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of 0.9% saline were administered over each 24h
and mannitol was used as required to maintain a
diuresis of greater than 100mlh-1. Four cycles of
treatment were given and patients were then
reassessed, according to the criteria described in the
EORTC urology group trial 30824 in which all
patients were entered. Magnesium status was
assessed prior to treatment by giving a loading dose
of magnesium sulphate (0.25mmolkg- 1 body
weight) in 250ml 0.9% saline over 1 h and
collecting urine for 24h. Excretion of more than
80% of the loading dose of magnesium was
assumed to indicate normal body stores, and
patients were stratified depending on their
magnesium excretion and then randomised to
receive magnesium supplements or no supplements
unless the serum magnesium fell to less than
0.45mmol1-1.
The level of supplementation was based on the
recommended daily intake of 8mmol magnesium
(DHSS, 1979) which was administered as
magnesium sulphate (8mmol in 500ml 0.9% saline
i.v. over 4h following cis-platin administration,
daily for 5 days). Oral supplements of magnesium
citrate 10mmol t.i.d. were commenced once the i.v.
infusion was discontinued, and these supplements
were continued until the next admission for
intravenous treatment. A magnesium citrate syrup
was formulated at Strathclyde University and
prepared by Pharmacy Department, Gartnavel
General Hospital. Thirty mmol of magnesium
administered orally daily was estimated to provide
patients with the recommended daily intake
allowing for 30% absorption (Wacker & Parisi,
1968). No attempt was made to provide a placebo
arm of supplements; however all clinical and
biochemical assessments of patients were made by
staff who were not aware at the time of whether or
not the patients were receiving supplements.
Creatinine clearance was measured before
treatment and was repeated prior to each course of
chemotherapy. Serum sodium, potassium,
creatinine, and magnesium were measured daily
during in-patient treatment; liver function tests,
serum calcium, plasma zinc and the tumour
markers human chorionic gonadotrophin and
alphafetoprotein were measured weekly. Sequential
urine collections (12h) were made during the 5 day
in-patient treatment and were analysed for NAG
activity and magnesium concentration. Twenty-four
hour dietary recall histories with computer analysis
were used to give an indication of how energy and
nutrient intake changed during and between cycles
(Trotter et al., 1981).
Results
Seventeen patients were studied in detail; the M:F
ratio was 16:1. Eight patients were randomised to
receive magnesium supplements, nine patients did
not receive supplements. Ages in the supplemented
group ranged from 18-39 years (mean 29 years), in
the non supplemented group ages ranged from 22-
47 years (mean 33 years). No patients were
magnesium deficient prior to treatment. One patient
in the supplemented group and two in the non
supplemented group had received pre-treatment
radiotherapy. Patients in each group received
similar total amounts of cis-platin (815mg for
supplemented group; 811 mg for non supplemented
group). The extent of metastatic disease was similar
in each group.
Table I summarises the main findings. There was
no significant difference in the numbers of complete
and partial responders to treatment in each group.
No patient developed clinical signs of hypo-
magnesaemia since intravenous or oral supplements
Table I Effects of magnesium supplementation after 4 cycles cis-platin treatment
Supplemented Non-Supplemented
Outcome patients patients
(8) (9)
A. Low volume metastases
complete response 5/5 100% 5/5 100%
partial response
died
B. High volume metastases
complete response 1/3 33% 1/4 25%
partial response 2/3 67% 2/4 50%
died 1/4 25%
Patients with treatment delays 3 38% 6 67%
Patients with neutropenic episodes 6 75% 8 90%
Patients with septicaemic episodes 2 25% 2 22%
Patients with anaemia requiring transfusion 2 25% 2 22%MAGNESIUM SUPPLEMENTATION DURING CIS-PLATIN THERAPY
were given when the serum magnesium fell to
0.45mmol 1- 1. Tumour markers decreased at similar
rates in each group indicating no difference in
response to treatment. There was a trend towards
fewer treatment delays in the magnesium supple-
mented group, although this was not statistically
significant. Neutropenic episodes which are often
the cause of delaying treatment showed a similar,
but not statistically significant trend. Septicaemic
episodes and the frequency of anaemia requiring
transfusion of blood occurred with similar frequency
in each group. Myelosuppression with neutropenia
and anaemia was more common in those patients
from both groups who had received pre-treatment
radiotherapy.
The magnesium data are summarised in Table II.
The serum magnesium data are shown in more
detail in Figure 1. Serum magnesium concentration
showed a significant difference (P<0.01) between
the lowest recorded levels in supplemented patients
and non-supplemented patients. Although the
lowest recorded serum potassium levels in the two
groups were not significantly different, all patients
in the non supplemented group required potassium
supplementation whereas only two patients in the
magnesium supplemented group required potassium
supplements at any time during the four cycles of
treatment. Serum calcium remained within the
reference range for both groups and liver function
tests were satisfactory throughout. There was no
significant change in plasma zinc. Mean urine NAG
activity during each course of cis-platin treatment is
summarised in Table III. Renal tubular damage as
assessed by urine NAG increased as treatment
continued in the non-supplemented group. Using a
non-parametric t-test urine NAG activity in the non
supplemented group was significantly higher than
the supplemented group (P<0.O1) by the third
course of treatment. This has previously been
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Figure 1 Lowest serum magnesium concentration
during each course of treatment. 0, Non-
supplemented group; 0, Non-supplemented group but
received magnesium supplements; 0, Supplemented
group and 0, Supplemented group but missed
magnesium supplements.
reported by our group (McAllister et al., 1985).
Creatinine clearance and serum creatinine levels
showed no significant changes between groups and
over the four courses of treatment. Urine
magnesium excretion was consistently higher in the
supplemented group (mean difference 6.6mmol
24h-1), but less than the magnesium supplements
given (8mmol 24h-1).
Dietary energy intake in both groups showed a
progressive fall from day 3 of cis-platin treatment,
slowly increasing for 10-12 days following
treatment to normal (Figure 2). There was a similar
pattern for all nutrients. Treatment restarted at day
16 of the post-treatment cycle, leaving few days of
improved intake to compensate for the 14 days of
reduced intake. Dietary intake did not differ
significantly between groups and showed even
Table II Serum and urine magnesium during magnesium supplementation
Lowest
serum magnesium Urine magnesium
(mean+s.d.) excretion (mean±s.d.)
mmol1-I mmol 24h-1
Course Without With Without With
number supplements supplements supplements supplements
1 0.67+0.08 0.70+0.06 3.3+0.5 9.8+1.4
2 0.62+0.13 0.66+0.09 3.1+0.5 10.6+1.0
3 0.50+0.07a 0.62+0.09a 3.2+0.7 9.5+1.0
4 0.51+0.13 0.60+0.12 3.3+0.9 9.4+0.6
a = P <0.01.
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Table III Urine NAG excretion during cis-platin treat-
ment
Urine NAG activity (mean-
(x upper limit reference ra
Course Without With
number supplements supplements
1 2.2+1.7 1.7+1.9
2 2.4+0.9 1.8+1.1
3 3.2+1.9 1.3+0.4
4 3.0+1.5 1.9+1.1
aSee text. NS=not significant.
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Figure 2 Comparison of energy intake
cycles 1 and 4 of cis-platin treatment (0
x x, cycle 4).
further fall (although not statistically sig
course 4 compared to course 1. Intake
with nausea, vomiting and anorexia al
were maximal during treatment and for
following treatment. Again these did
between groups. Weight losses did
significantly between the groups
supplemented group showing a range o
(mean, 10kg) and the non-supplemer
showing a range of 2-25kg (mean, I
patient in the supplemented group gai
(3kg). No side effects of magnesium s
were reported by patients, although
magnesium citrate syrup was pronoun
'metallic' and 'unpleasant to take'. Seve
stopped taking oral supplements for the
There was no gastrointestinal upset asso
the supplements.
Supplementation of magnesium in cancer patients
+ s.d.) receiving cis-platin appears to be beneficial with Cnge) reduced renal tubular damage and fewer treatment
5ignificance delays. There is no evidence of increased tumour
relative to growth, poorer outcome, or any other harmful
course I effects to patients receiving magnesium supplements.
Previous studies on our group of cancer patients
report a 43% incidence of anorexia (Willox et al.,
NS 1984) plus a 73% incidence of deficiencies of all
P <0.01 dietary components with a 78% incidence of
specific dietary magnesium deficiency in out
patients (Trotter et al., 1981) and an 80% incidence
in in-patients (Willox, 1984). A 37% incidence of
low serum magnesium levels has been shown in this
group (Willox, 1984). These background data,
Cisplatin together with the marked anorexia and weight loss
treatment
found in patients receiving cis-platin, increase the
probability of these patients developing serum and
L it - A - ; _ _ A U<oay malgnesuml aeticiencies auring treatmejit. A
retrospective review of our patients treated with cis-
platin revealed that all patients developed
hypomagnesaemia (McAllister et al., 1981).
Macaulay et al. (1982) proposed magnesium
supplementation during in-patient intravenous
chemotheranv onlv: however this Dresent studv
showed progressive decrease in serum magnesium
15 1'7' 19 levels as treatment continued in all patients,
including those receiving intravenous and oral
supplements. The optimum level of supplemen-
tation, and finding an acceptable and palatable
oral supplement were beyond the scope of this
-s between study. However, the significant difference in serum
-0, cycle 1; magnesium levels between those on and those off
supplements, and the lower serum magnesium
levels found in those patients supplied with oral
supplements which they were not taking points to
continuous supplementation as the method of
,nificant) in choice. It is probable that the difference between
correlated the two groups would have been considerably
11 of which greater if 6 of the 8 non-supplemented patients had
two weeks not received supplements when the concentration of
not differ magnesium in serum decreased to 0.45mmoll-1 by
not differ course 3 or 4. Short periods of intravenous
with the supplements are unlikely to be able to compensate
f 8-12.5kg for the longer periods of poor dietary intake;
ated group instead they are likely to lead to an increase in
1I kg). One urinary magnesium loss while keeping the serum
ned weight magnesium levels temporarily within the normal
,upplements reference range. Oral supplementation may well
the oral also be required. It should be noted that the non-
ced 'bitter' supplemented group continued to excrete similar
ral patients amounts of magnesium despite low concentrations
,se reasons. of magnesium in serum. The patients appear to
ciated with have an obligatory urine magnesium loss, perhaps
due to the high fluid load, perhaps due to drug
Discussion
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damage. Schilsky et al. (1982) have shown
prolonged hypomagnesaemia following cis-platin
treatment and long term follow up of magnesium
supplemented patients in Glasgow will be
interesting.
The number of patients included in this study
was unfortunately small due to the number of
patients referred for chemotherapy and the time
available for the study to be performed. As a result
it is impossible to assess the effects of supplemen-
tation in patients with low and high volume
metastases separately. Although magnesium sup-
plementation appears to be beneficial for all
patients, it is likely that the greatest benefit will be
to patients with large volume metastatic disease
who may require prolonged treatment withl cis-
platin. Minimising treatment delays and renal
damage in these patients is essential.
Magnesium supplementation should however
become a routine part of cis-platin therapy. Further
studies to examine the best methods of supplemen-
tation are indicated.
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